Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03040141 · ClinicalTrials.gov registry record · Phase 2

Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A

A Phase 2 study of Influenza a, sponsored by Visterra.

Completed
Registry status
Phase 2
Development phase
89
Enrollment target
20
Study locations

NCT03040141 is a Phase 2 study of Influenza a that has completed, run by Visterra. The registered enrollment target is 89 participants, below the 2,745-participant average among 10 other Influenza a trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03040141, a Phase 2 study of Influenza a, has completed, sponsored by Visterra.

COMPLETED
Registry status
Phase 2
Development phase
89 participants
Enrollment target
20
Study locations

Study Summary

This study is to compare the efficacy and safety of VIS410 in combination with oseltamivir vs oseltamivir alone in severely ill subjects with influenza A infection requiring oxygen support.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Low dose of VIS410
  • DRUG High dose of VIS410

Study Locations (20)

Pennsylvania

  • Visterra - Allentown
  • Visterra - Philadelphia
  • Visterra - York

Georgia

  • Visterra - Atlanta
  • Visterra - Decatur

New York

  • Visterra - Albany
  • Visterra - Syracuse

North Carolina

  • Visterra - Durham
  • Visterra - Greensboro

Ohio

  • Visterra - Cleveland
  • Visterra - Columbus

Arizona

  • Visterra - Tucson

California

  • Visterra - Stanford

Florida

  • Visterra - St. Petersburg

Trial Details

FieldValue
Enrollment Target 89 participants
Start Date 2018-01-03
Est. Completion 2018-11-22
Phase Phase 2

Sponsor

Visterra

4 total trials

What the Registry Record Tells You About NCT03040141

The ClinicalTrials.gov registry entry for NCT03040141 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,745-participant average among 10 other Influenza a trials with a reported enrollment target (97% lower). The listed sponsor is Visterra, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Influenza a appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT03040141 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Pennsylvania, Georgia, New York.

Frequently Asked Questions

What is clinical trial NCT03040141 about?

NCT03040141 is a clinical study titled "Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A". This study is to compare the efficacy and safety of VIS410 in combination with oseltamivir vs oseltamivir alone in severely ill subjects with influenza A infection requiring oxygen support.

What is the current status of trial NCT03040141?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2018-01-03. Estimated completion is 2018-11-22.

What conditions does trial NCT03040141 study?

This clinical trial studies the following conditions: Influenza a.

What interventions are being tested in trial NCT03040141?

The interventions under investigation include: Placebo (DRUG), Low dose of VIS410 (DRUG), High dose of VIS410 (DRUG).

Who is sponsoring clinical trial NCT03040141?

This trial is sponsored by Visterra, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03040141 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Influenza a

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.